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OBJECTIVES The purpose of this study was to evaluate the association between hypertension and left
ventricular hypertrophy (LVH) with both coronary vascular remodeling and endothelial function.
BACKGROUND The association between endothelial and nonendothelial coronary flow reserve with vascular
remodeling in patients with hypertension and LVH is still unclear.
METHODS One hundred and eleven patients with normal or mildly diseased coronary arteries at
angiography underwent intravascular ultrasound examination of the left anterior descending
coronary artery. Patients were divided into three groups: group 1: n 5 13, hypertensive
patients with LVH; group 2: n 5 30, hypertensive patients without LVH; group 3: n 5 68,
normotensive patients. Vessel and lumen area and atherosclerotic plaque area were evaluated.
Vascular reactivity was examined using intracoronary adenosine and acetylcholine.
RESULTS Vessel area in group 1 (with LVH) was significantly (p , 0.01) greater than that in group 2
(without LVH), whereas, vessel area in both groups 1 and 3 was similar (12.8 6 0.8 mm2,
10.7 6 0.4 mm2 and 11.5 6 0.3 mm2). Coronary blood flow at baseline for patients in group
1 (with LVH) was significantly greater than it was for patients in groups 2 and 3 (81.1 6
9.9 ml/min, 56.5 6 6.2 ml/min and 48.1 6 3.2 ml/min, both p , 0.05). In comparison with
groups 2 and 3, the response to both acetylcholine and adenosine was significantly impaired
in patients with LVH.
CONCLUSIONS The current study demonstrates that hypertension with LVH is associated with both coronary
vascular remodeling and attenuated endothelial and nonendothelial coronary flow reserve.
(J Am Coll Cardiol 2000;35:1654–60) © 2000 by the American College of Cardiology
Arterial hypertension is the most common cause of chronic
pressure overload of the left ventricle, and left ventricular
hypertrophy (LVH) represents the general structural mech-
anism of cardiac adaptation in response to chronic pressure
overload. Left ventricular hypertrophy is associated with an
increased incidence of adverse cardiovascular events (1).
Potential mechanisms that might account for this observa-
tion include increased vulnerability of the hypertrophied
myocardium to ischemic damage and enhanced arrhythmo-
genesis (2–5). Moreover, patients with hypertension and
LVH have signs and symptoms of myocardial ischemia in
the absence of significant coronary stenoses (6–8). This
may be related to reduced coronary vasodilator capacity
(7–9), and, indeed, some investigators demonstrated that, in
the absence of obstructive coronary artery disease, the
endothelium-dependent vasodilation in both epicardial and
resistance coronary arteries was impaired in hypertensive
disease (10–13). Coronary vascular remodeling is an active
process in hypertension and LVH; in response to increased
arterial pressure, the vessel structure may be altered. The
increase in luminal dimensions with LVH may represent an
adaptive response to maintain coronary flow velocity and shear
stress constant (14–16). However, the association between
these structural and functional alterations in the coronary
circulation in patients with hypertension and LVH is not clear.
The purpose of this study was to assess the association
between hypertension and LVH with both coronary vascu-
lar remodeling and endothelial and nonendothelial coronary
flow reserve (CFR).
METHODS
Study population. One-hundred and eleven patients who
had been referred for cardiac catheterization to exclude
coronary artery disease were prospectively studied. Patients
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were included in this study if they had the following: 1)
angiographically smooth arteries, 2) mild irregularities with
no coronary artery lesion .30% lumen diameter stenosis by
visual assessment in any major epicardial vessel, and 3) the
proximal coronary arteries were .2.0 mm in diameter.
Patients with an obvious history of variant angina, previous
myocardial infarction, previous coronary artery bypass graft-
ing or coronary intervention were excluded from this study.
Long-acting nitrates, angiotensin converting enzyme inhib-
itors or calcium channel blocking agents were withheld for
at least 48 h before the study.
The 111 patients of this study were divided into three
groups according to their history of hypertension and the
presence of hypertensive LVH assessed by echocardiogram.
Group 1 consisted of 13 patients who had hypertension
with LVH. Group 2 consisted of 30 patients with hyper-
tension without LVH. Group 3 consisted of 68 patients
without hypertension. The study was approved by the Mayo
Clinic Institution Review Board.
Definition of hypertension and LVH. Patients were con-
sidered to have systemic hypertension if they had a history
of elevated blood pressure requiring long-term therapy. Left
ventricular hypertrophy was defined as posterior wall thick-
ening .13 mm on echocardiogram in hypertensive patients
or increased left ventricular mass (LVM) index (LVMI)
g/m2 (17). Left ventricular mass was measured according to
the following equation LVMI 5 1.04 ([LVID 1 IVS 1
PW]3 2 LVID3) 2 13.6 divided by the body surface area,
where LVID 5 left ventricular internal dimension at
end-diastole, IVS 5 septal thickness at end-diastole and
PW 5 posterior wall (17). The control blood pressure in a
drug-free period at the time of cardiac catheterization was
recorded in all patients. At this time patients with and
without hypertension had a mean arterial blood pressure of
111 6 2 and 102 6 2 mm Hg, respectively (p , 0.01).
Study protocol. Diagnostic coronary angiography was per-
formed using a 6F Judkins catheter with a standard femoral
percutaneous approach. Twenty-five hundred U of heparin
were administered at the beginning of the procedure. Nonionic
contrast material was used for all patients. No nitroglycerin was
given before the diagnostic procedure.
Coronary blood flow reserve in response to acetylcholine
and adenosine was studied according to a previously re-
ported protocol (18–20). After control coronary angiograms
had been obtained, a 0.014 in. Doppler guidewire (Cardio-
metrics, Santa Anna, California) was introduced through an
8F guiding catheter into the left anterior descending coro-
nary artery. Once baseline flow velocity data were obtained
at the position after a stable Doppler signal was obtained, a
bolus of intracoronary adenosine (18–54 mg: solution of
6 mg adenosine in one liter of saline) was administered until
a plateau was achieved. Then selective intracoronary infu-
sion of increasing concentrations of acetylcholine (1026,
1025 and 1024 mol/liter) was performed for a total duration
of 3 min through a 2.2F Tracker coronary infusion catheter
(SciMed Life System, Maple Grove, Minnesota) over a
0.014 in. Doppler guidewire (21). Symptoms, hemody-
namic data, electrocardiogram and Doppler velocities were
recorded at the end of each infusion. If there was severe
constriction of the coronary arteries with any dose of
acetylcholine, the infusions were stopped. Just before the
end of each dose of acetylcholine, angiography was repeated.
After infusions of acetylcholine, 300 mg of nitroglycerin was
given by an intracoronary route, and angiography was
repeated within 2 min after the nitroglycerin was given. The
coronary angiograms were performed in the same projection
as the baseline coronary angiogram.
Intravascular ultrasound examination. One of three intra-
coronary ultrasound systems (Endosonics, Rancho Cordova,
California; Cardiovascular Imaging Systems and Hewlett-
Packard, Boston, Massachusetts) was used in this study.
Details of these systems have been described elsewhere (22,23).
The intracoronary ultrasound catheters were inserted through
the 8F guide catheter and placed into the proximal and middle
portion of the left anterior descending artery over a 0.014-in.,
high torque floppy guidewire (Advanced Cardiovascular Sys-
tems, Sunnyvale, California). After optimization of the ultra-
sound image, continuous real-time images were recorded on
0.5-in. videotape. Four to five segments of the left anterior
descending coronary artery were identified.
Quantitative coronary angiography. Analysis of artery
diameter from the cine films was done with a modification
of the technique previously described by this institution
(18,24,25). These measurements were made with no knowl-
edge of the ultrasound findings.
Assessment of coronary blood flow. Doppler flow velocity
spectra were analyzed on-line to determine time-averaged
peak velocity. Coronary flow reserve (CFR) to adenosine
was calculated as the ratio of hyperemic to basal average
peak velocity of the distal vessel. Volumetric coronary blood
flow (CBF) was determined from the relation: CBF 5
cross-sectional area 3 average peak velocity 3 0.5 (26).
Endothelial-dependent coronary flow reserve was calculated
Abbreviations and Acronyms
BSA 5 body surface area
CBF 5 coronary blood flow
CFR 5 coronary flow reserve
IVS 5 septal thickness at end-diastole
LVDd 5 left ventricular end-diastolic
LVDs 5 left ventricular end-systolic
LVH 5 left ventricular hypertrophy
LVID 5 left ventricular internal dimension at end-
diastole
LVM 5 left ventricular mass
LVMI 5 left ventricular mass index
PW 5 posterior wall
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as percent change in CBF in response to acetylcholine, as
previously described (19,20). Coronary vascular resistance
was calculated as the mean arterial pressure divided by the
CBF.
Intracoronary ultrasound image analysis. An off-line
computer-interactive analysis system was used to digitize
the intracoronary ultrasound video images onto a 256 3
256-bit matrix. All the data were analyzed without knowl-
edge of the patients history of hypertension and LVH.
Standard calibration markers directly from the ultrasound
image were used for calibration of absolute measurements.
Measurements of area stenosis and minimal lumen diameter
were made of the most severely stenosed region at each
specific segment of the artery that had been previously
identified. With computer planimetry, the specific segment
was assessed quantitatively. The external elastic membrane
cross-sectional area, which represents the area within the
border between the hypoechoic media and echoreflective
adventitia, was a measure of total arterial cross-sectional
area (vessel area). Because intravascular ultrasound cannot
measure media thickness accurately, plaque plus media
cross-sectional area (plaque area), which was calculated as
external elastic membrane cross-sectional area (vessel area)
minus lumen cross-sectional area (lumen area), was used as
a measure of plaque mass. Percent area stenosis was calcu-
lated as the ratio of plaque plus media to external elastic
membrane cross-sectional area. Morphologic plaque fea-
tures were classified according to the following definitions
by consensus. Segments that had concentric prominent
leading edge echo and widened subintimal echolucent zone,
with combined thickness ,0.3 mm, were classified as
normal. Soft plaque was less dense than the reference
adventitia. Fibrous plaque is composed of thickened dense
echoes involving the intimal leading edge with homogenous
echodensity equal to that seen for the adventitia. Hard
plaque was more dense than the reference adventitia and
had no acoustic shadowing. Calcific tissue produced bright
echoes with acoustic shadowing. In segments with a calcium
arc .90°, the external elastic lamina was not traced because
of potential inaccuracy due to shadowing and were excluded
from further analysis.
Inter- and intraobserver variability. Two ultrasound sites
from 10% of the patients studied were randomly selected
and measured by the same observer on two separate occa-
sions and also by a second observer. These measurements
were then used to evaluate intra- and interobserver variabil-
ity on two separate occasions and also by a second observer.
These were expressed as linear regression between the two
observations and as percent error, derived as the absolute
difference between observations.
Statistical analysis. Values are expressed as the mean 6 1
SEM. Statistical significance was accepted when the prob-
ability value was p , 0.05. The relationship between two
parameters was evaluated with a linear regression analysis.
Comparisons of the baseline cardiovascular risk variables
between the three groups were done with the Pearson’s
chi-square test. Comparisons of hemodynamic and echo-
cardiographic data between the study groups were done
with one-way analysis of variance.
RESULTS
One-hundred and eleven patients with normal and mildly
diseased coronary arteries were studied. Thus, a total of 397
segments of 111 patients were evaluated.
Patient characteristics. Gender distribution, age and body
surface area (BSA) were similar in the three groups. With
regard to other coronary risk factors, there was no difference
among the study group. Systolic and mean blood pressure at
time of catheterization in groups 1 and 2 were similar and
significantly greater than those in group 3 (both p , 0.01
and p , 0.05, respectively). Left ventricular posterior wall
thickness as well as LVMI in group 1 was significantly
higher than that in group 2 (p , 0.01). There was no
difference in left ventricular end-diastolic (LVDd) and left
ventricular end-systolic (LVDs) dimensions between groups
1 and 2 (Table 1).
Intravascular ultrasound data. The dimensions of vessel
area: the external elastic membrane cross-sectional area that
represents the area within the border between the hypo-
echoic media and echoreflective; lumen area: lumen cross-
sectional area and plaque area: plaque plus media cross-
sectional area, which was calculated as vessel area minus
lumen area of the three groups, are shown in Figure 1.
Plaque area was not significantly different between the three
groups: 3.8 6 0.4 mm2 (group 1), 3.4 6 0.2 mm2 (group 2)
and 3.2 6 0.2 mm2 (group 3). However, lumen area in the
patients with LVH (group 1) and the normotensive patients
(group 3) was similar and significantly (p , 0.01 and p ,
0.05, respectively) larger than that in group 2: 9.0 6 0.6
mm2 (group 1), 7.4 6 0.3 mm2 (group 2) and 8.4 6 0.2
mm2 (group 3). In addition, vessel area in group 1 was
significantly (p , 0.01) bigger than that in hypertension
patients without LVH (group 2): 12.8 6 0.8 mm2 (group
1), 10.7 6 0.4 mm2 (group 2) and 11.5 6 0.3 mm2 (group
3).
Vessel area significantly increased with plaque area in all
three groups. Vessel area in the three groups increased 1.39
mm2, 1.13 mm2 and 1.33 mm2 for every 1-mm2 increase in
plaque area, suggesting that the vessel enlarges in response
to plaque accumulation (r 5 0.66, p , 0.0001; r 5 0.67,
p , 0.0001 and r 5 0.64, p , 0.0001, respectively).
Percent area stenosis, maximal thickness of plaque and
plaque composition are shown in Table 2. Percent area
stenosis in group 3 was significantly smaller than that in
group 2 (p , 0.05). With regard to plaque composition, the
three groups did not differ in any type of plaque.
The interobserver variability was 0.4 6 2.4% and 1.06 6
4.3% for the coronary diameter and area measurements,
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respectively, and the intraobserver variability was 0.8 6
1.9% and 1.5 6 3.3% for the coronary diameter and area
measurements, respectively.
Changes in CBF. Baseline CBF in group 1 was signifi-
cantly greater than that in groups 2 and 3 (p , 0.05 and p ,
0.01, respectively). The coronary vascular resistance was
significantly reduced in group 1 in comparison with the
other groups (1.7 6 0.3, 2.7 6 0.3 and 2.9 6 0.2
respectively, both p , 0.05). Furthermore, there was sig-
nificant correlation between LVH assessed by left ventric-
ular mass and baseline CBF (Fig. 2). The percent increases
in CBF induced by acetylcholine in group 1 were signifi-
cantly smaller than those in group 3 (p , 0.01) and tended
to be smaller but not significantly so than those in group 2
(p 5 0.18), suggesting that endothelium-dependent vaso-
dilation in hypertensive patients with LVH was impaired.
The calculated CFR examined using adenosine in group 1
was significantly smaller than that in groups 2 and 3 (p ,
0.05 and p , 0.01, respectively), suggesting that the dilator
Table 1. Patient Characteristics
Group 1 Group 2 Group 3
Hypertension
With LVH
Hypertensive
Without LVH Normotensive
No. of patients n 5 13 n 5 30 n 5 68
Men 3/13 (23%) 10/30 (33%) 30/68 (44%)
Age (yr) 55 6 3 53 6 2 50 6 2
BSA (m2) 1.79 6 0.06 1.90 6 0.03 1.91 6 0.03
Risk factors
Hypercholesterolemia 8/13 (62%) 18/30 (60%) 27/68 (40%)
Diabetes 1/13 (8%) 2/30 (7%) 8/68 (12%)
Smoking 5/13 (38%) 18/30 (60%) 40/68 (59%)
Family history 8/13 (62%) 19/30 (63%) 42/68 (62%)
Postmenopause 7/13 (54%) 15/30 (50%) 23/68 (34%)
Hemodynamics data
Systolic BP (mm Hg) 156 6 7† 147 6 4‡ 133 6 3
Diastolic BP (mm Hg) 85 6 3 83 6 2 79 6 1
Mean BP (mm Hg) 114 6 4† 110 6 3‡ 102 6 2
Echocardiographic data
LVDd (mm) 45.8 6 1.3 48.3 6 1.0
LVDs (mm) 27.8 6 1.2 29.8 6 1.3
LVPW (mm) 13.5 6 0.2* 9.6 6 0.2
LVMI (g/m2) 165 6 7.6* 141.2 6 7.2
Values are mean 6 SE. BP 5 blood pressure; BSA 5 body surface area; LVDd and LVDs 5 left ventricular end-diastolic and
end-systolic dimension; LVH 5 left ventricular hypertrophy; LVMI 5 left ventricular mass index; LVPW 5 left ventricular post
wall thickness.
*p , 0.01 versus group 2; †p , 0.01; ‡p , 0.05 versus group 3.
Figure 1. Mean (6SE) vessel area, lumen area and plaque area in
the three study groups. *p , 0.01 for the comparison with group
3; 2. HTN 5 hypertension; LVH 5 left ventricular hypertrophy.
Table 2. Plaque Characteristics
Group 1 Group 2 Group 3
Hypertensive
With
LVH
Hypertensive
Without
LVH Normotensive
No. of segments n 5 42 n 5 104 n 5 251
Percent area
stenosis (%)
29.4 6 2.3 30.0 6 1.5 26.4 6 0.9*
Maximal plaque
thickness (mm)
0.58 6 0.06 0.59 6 0.04 0.52 6 0.03
Plaque composition
Soft 19/29 (66%) 39/69 (57%) 103/154 (67%)
Fibrous 5/29 (17%) 20/69 (29%) 29/154 (19%)
Hard 1/29 (3%) 3/69 (4%) 8/154 (5%)
Mixed 4/29 (14%) 7/69 (10%) 14/154 (9%)
Values are mean 6 SE. LVH 5 left ventricular hypertrophy. *p , 0.05 vs. group 2.
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capacity of the coronary microcirculation in hypertensive
patients with LVH was attenuated (Table 3 and Fig. 3).
However, there was no significant correlation between
maximal plaque thickness and endothelial function (r 5
0.04) or endothelial-independent CFR (r 5 0.05).
DISCUSSION
This study demonstrates for the first time in humans with
hypertension and LVH that functional abnormalities in
CFR are associated with structural changes.
Effects of LVH on CBF and vascular reactivity. Several
studies have shown that the endothelium is functionally
abnormal in hypertensive patients (12,27,28). In response
to infusion of acetylcholine, our study showed that
endothelium-dependent vasodilation of resistance coronary
arteries was nearly identical among normotensive patients
and hypertensive patients without LVH. Our results are
consistent with the previous studies that arterial hyperten-
sion without established LVH had no apparent effect on
acetylcholine-induced increases in CBF (29,30). However,
hypertensive patients with LVH demonstrated significantly
attenuated response to acetylcholine. Additionally, a history
of hypertension had no apparent effect on CBF responses to
adenosine in our patients, who had no evidence of LVH.
However, the presence of LVH was associated with signif-
icant impairment of adenosine-induced CBF responses.
Furthermore, CBF at rest in patients without LVH or
normotensive patients were similar and was significantly
smaller when compared with hypertensive patients with
LVH. These results are consistent with previous studies that
CBF is increased in patients with LVH (31,32). Therefore,
in hypertensive patients with LVH, the increased basal CBF
to the hypertrophied myocardium leads to the reduction of
its functional vasodilator capacity. The attenuated responses
to acetylcholine and adenosine in the LVH group do not
necessarily mean that endothelial function is altered. It may
Table 3. Coronary Hemodynamic Characteristics
Group 1 Group 2 Group 3
Hypertensive
With LVH
Hypertensive
Without LVH Normotensive
No. of patients n 5 13 n 5 30 n 5 68
CBF at baseline (ml/min) 81.1 6 9.9*† 56.5 6 6.2 48.1 6 3.2
Coronary flow reserve to adenosine 2.3 6 0.2*† 2.7 6 0.1 2.8 6 0.1
Coronary vascular resistance
(mm Hg min/ml)
1.7 6 0.3*‡ 2.7 6 0.3 2.9 6 0.2
CBF change induced by acetylcholine
(min/ml)
99.3 6 29.0 78.1 6 11.5 69.8 6 6.8
% change of CBF induced by
acetylcholine (%)
1.5 6 20.5† 46.9 6 20.2 56.1 6 13.1
% change of CAD induced by
acetylcholine (%)
231.6 6 9.5 211.3 6 5.4 212.3 6 4.2
Values are mean 6 SE.
CAD 5 coronary artery diameter; CBF 5 coronary blood flow; LVH 5 left ventricular hypertrophy.
*p , 0.05 versus group 2; †p , 0.01; ‡p , 0.05 versus group 3.
Figure 2. The relationship between baseline coronary blood flow
(CBF) (ml/min) and left ventricular mass (LVM) index (g/m2).
Figure 3. Coronary flow reserve (CFR) in response to adenosine
among the study groups. There was significant impairment of
CFR in patients with hypertension and left ventricular hypertro-
phy (LVH) compared with that of the other groups (p , 0.05).
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be speculated that there is maximal endothelial and nonen-
dothelial coronary vasodilation to supply increased CBF in
order to meet the increased myocardial demand. This
hypothesis is supported by the current observation that the
coronary vascular resistance was significantly reduced in
patients with hypertension with LVH. Thus, with further
increase in myocardial demand, myocardial ischemia may
occur.
Structural vascular alterations in LVH. Hypertensive
vessels are characterized by thickened media, reduced lumen
and increased extracellular matrix (33,34). The observation
in our study of the reduction in lumen area in hypertensive
patients without LVH when compared with that in normo-
tensive patients is consistent with these studies. Addition-
ally, vessel and lumen area in hypertensive patients with
LVH were significantly enlarged compared with those in
hypertensive patients without LVH. These results corre-
spond to previous necropsy studies that had reported an
increase in coronary artery diameter in hypertrophied hearts
(35,36). These data indicate that lumen and vascular area
vary with changing blood flow in hypertensive patients with
LVH. This study, however, did not address the structural
abnormalities of the intramyocardial arterioles because his-
tologic analysis was not made.
Mechanisms of coronary remodeling. In normal subjects,
the internal diameter of normal coronary arteries is corre-
lated to blood flow, and changes result mainly from remod-
eling of the arterial wall (37). The increase in lumen area
appears to establish a constant blood flow velocity in the
large epicardial coronary artery despite increased total CBF.
The maintenance of constant blood flow velocity would
maintain normal endothelial function because arterial en-
dothelium appears to be sensitive to shear stress (38). The
shear stress mediates the release of the endothelium-derived
relaxing factor (39,40). It has been suggested that
endothelium-derived relaxing factor is a potent vasodilator
(41) that inhibits growth factor stimulated proliferation of
vascular smooth muscle cells (42), endothelial movement
(43) and extracellular matrix production (44). Thus,
endothelium-derived relaxing factor has many of the
attributes necessary to suggest its role as a mediator of
vascular remodeling. Vascular remodeling with compen-
satory coronary enlargement tends to normalize coronary
flow velocity and, thus, shear stress, resulting in a reduced
release of the endothelium-derived relaxing factor.
Therefore, chronic epicardial coronary enlargement may
be an adaptation to chronically increased release of the
endothelium-derived relaxing factor in hypertensive
LVH.
Study limitations. This study is a cross-sectional study,
and its findings may warrant confirmation through a pro-
spective study. Moreover, the administration of intracoro-
nary adenosine rather than intravenous administration pre-
vents us from assessing the coronary vascular resistance
ratio.
Clinical implications. Reduced CFR is an important fea-
ture of hypertrophied ventricle. Although this reduced CFR
may not affect left ventricular function at rest, it could cause
impaired subendocardial wall function and reduced suben-
docardial coronary perfusion during periods of stress in the
hypertrophied myocardium. Repeated stress and subendo-
cardial ischemia lead to subendocardial fibrosis, which also
impairs systolic function. Both the subendocardial ischemia
and fibrosis alter left ventricular diastolic function, thereby
also impairing systolic function. All of these mechanisms are
linked by reduced CFR, which accelerate the progression
from compensated left ventricular hypertrophy to failure
(45,46).
Conclusions. The effect of left ventricular hypertrophy on
lumen area may result not from a decrease in plaque area but
rather an increase in vessel area reflecting vascular remod-
eling in hypertensive LVH. Additionally, these structural
changes occur in association with impairment of both
endothelium dependent and independent vasomotion re-
sponses, which could be caused by maximal coronary vaso-
dilation at the level of the resistance vessels. Therefore, in
humans with hypertension and LVH, functional abnormal-
ities in CFR are associated with structural changes.
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